Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price shot up 6.5% during mid-day trading on Wednesday . The stock traded as high as $15.84 and last traded at $15.83, with a volume of 328,113 shares changing hands. The stock had previously closed at $14.86.

Several brokerages have recently issued reports on BLCM. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Zacks Investment Research upgraded Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Finally, SunTrust Banks Inc. began coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $27.50.

The company’s market capitalization is $431.28 million. The firm has a 50 day moving average of $13.47 and a 200-day moving average of $11.21.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, equities research analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current year.

In other news, COO Annemarie Moseley sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total value of $325,000.00. Following the transaction, the chief operating officer now directly owns 18,486 shares of the company’s stock, valued at approximately $240,318. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Ken Moseley sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total value of $195,000.00. Following the completion of the transaction, the vice president now directly owns 15,196 shares in the company, valued at $197,548. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley raised its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent quarter.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.